Jan 11, 2023. In CELLPRESS, Cell Host and Microbe
Title: Rethinking next-generation vaccines for coronaviruses, influenza viruses,and other respiratory viruses
Authors, David M. Morens, (Anthony Fauci's replacement?) Jeffery K. Taubenberger (Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NationalInstitutes of Health), and Anthony S. Fauci
Introduction:
...Viruses that replicate in the human respiratory mucosa without infecting systemically, including influenza A, SARS-CoV-2, endemic coronaviruses, RSV, and many other ‘‘common cold’’ viruses... have not to date been effectively controlled by licensed or experimental vaccines.
...As of 2022, after more than 60 years of experience with influenza vaccines, very little improvement in vaccine prevention of infection has been noted
Conclusion:
...Durably protective vaccines against non-systemic mucosal respiratory viruses with high mortality rates have thus far eluded vaccine development efforts.
